The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In the Archives

Advocacy and advances: The DOD Breast Cancer Research Program, immunotherapy, and annual reports

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Spotlight article

Advocacy in Action: The DOD Breast Cancer Research Program
By National Breast Cancer Coalition | September 2, 2021

At first glance, the Department of Defense and breast cancer research might not seem like an easy or natural fit.

And that’s just how the National Breast Cancer Coalition (NBCC) would have it. NBCC is an organization that pushes against the status quo, so finding innovative solutions to complicated problems is a hallmark of their work. The Department of Defense Breast Cancer Research Program (DOD BCRP) is an example of how NBCC advocates pushed boundaries to pursue critical research funding and changes to the system of research that incorporate advocates and support meaningful results.

Recent contributions

Thomas Dougherty, PhD: Pioneer of Photodynamic Therapy
By Roswell Park Comprehensive Cancer Center | September 2, 2021

Documentary profiles Dr. James P. Allison and his Nobel Prize-winning immunotherapy research
By ASCO | September 2, 2021

Fran Visco: President of the National Breast Cancer Coalition
By National Breast Cancer Coalition | September 1, 2021

ASCO Clinical Cancer Advances

Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2009: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2008: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2007: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2006: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

Clinical Cancer Advances 2005: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
By ASCO | September 1, 2021

This column features the latest posts to the Cancer History Project by our growing list of contributors. 

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account